ccl28  (R&D Systems)

Journal: bioRxiv

Article Title: IgE-producing cells on the move: CCR2 is a key regulator of IgE + plasma cell migration

doi: 10.64898/2025.12.18.695109

Figure Lengend Snippet: (A) Representative histograms showing surface CCR10 expression on IgE + (red) and IgG1 + (blue) gated cells; the filled grey histogram shows the isotype control staining. The accompanying graph shows CCR10 MFI on the gated IgE + and IgG1 + cells. (B) Representative plots of CCR10 expression on IgE + and IgG1 + GC-like B cells, PBs, and PCs. CCR10 MFI across the different IgE + and IgG1 + cell populations from several experiments. (C) The dot plots show the frequency of IgE + and IgG1 + cells after 3h of migration in response to RPMI only or two different concentrations of CCL28, 25nM (300 ng/mL) and 125nM (1.5 μg/mL). (D) CCL28 induced migration shown as a percentage of the IgE + and IgG1 + cells migrating in response to RPMI control. (E) The migration capacity of IgE + and IgG1 + GC-like B cells, plamablasts, and PC in response to CCL28. (F) CCL28 induced migration shown as a percentage of the cells migrating in response to RPMI control. Data are mean + s.d. Statistical analysis was performed using one-way ANOVA with Tukey’s multiple comparison test (B, D, F) or paired two-tailed t -test with Welch’s correction (A); *p< 0.05; **p< 0.01.

Article Snippet: More specifically, we tested the migration of IgE + and IgG1 + cells in response to recombinant human CXCL12 (R&D systems; 300ng/mL), CCL2 (Biolegend; 10ng/mL, 100ng/mL and 300ng/mL) and CCL28 (R&D systems; 300ng/mL and 1.5ug/mL).

Techniques: Expressing, Control, Staining, Migration, Comparison, Two Tailed Test

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

doi: 10.1186/s13046-024-03135-3

Figure Lengend Snippet: Fig. 2 Tumor-derived CCL28 recruits pericytes to promote vascular normalization in the tumor microenvironment

Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

Techniques: Derivative Assay

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

doi: 10.1186/s13046-024-03135-3

Figure Lengend Snippet: Fig. 3 Tumor-derived CCL28 promotes the expression of angiopoietin-1 via CCR3 in pericytes

Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

Techniques: Derivative Assay, Expressing

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

doi: 10.1186/s13046-024-03135-3

Figure Lengend Snippet: Fig. 6 CCL28 is involved in bevacizumab-mediated vascular normalization

Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

Techniques:

Journal: Journal of experimental & clinical cancer research : CR

Article Title: Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.

doi: 10.1186/s13046-024-03135-3

Figure Lengend Snippet: Fig. 7 A schematic diagram of tumor microenvironment modulation effects of CCL28

Article Snippet: Chromatin Immunoprecipitation (ChIP) Briefly, pericytes treated with or without recombinant human CCL28 or CCR3 (R&D Systems, MAB155-100) neutralizing antibodies were collected and fixed by adding a cross-linking agent, formaldehyde, to stabilize the interactions between chromatin proteins and DNA.

Techniques:

Journal: Renal Failure

Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

doi: 10.1080/0886022x.2024.2313171

Figure Lengend Snippet: Figure 1. Plasma and urine CCL2 levels between AKI and non-AKI patients at hospital and ICU admission. **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

Techniques: Clinical Proteomics

Journal: Renal Failure

Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

doi: 10.1080/0886022x.2024.2313171

Figure Lengend Snippet: Figure 2. The predictive performance of urine CCL2 for AKI by ROC analysis. (A) ROC curve. (B) AUC and prediction sensitivity and specificity.

Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

Techniques:

Journal: Renal Failure

Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

doi: 10.1080/0886022x.2024.2313171

Figure Lengend Snippet: Figure 3. Plasma and urine CCL2 levels between SAKI and non-septic AKI patients at hospital and ICU admission. ***p < 0.001.

Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

Techniques: Clinical Proteomics

Journal: Renal Failure

Article Title: Assessment of urine CCL2 as a potential diagnostic biomarker for acute kidney injury and septic acute kidney injury in intensive care unit patients

doi: 10.1080/0886022x.2024.2313171

Figure Lengend Snippet: Figure 4. The predictive performance of urine CCL2 for SAKI by ROC analysis. (A) ROC curve. (B) AUC and prediction sensitivity and specificity.

Article Snippet: The CCL2 levels in plasma and urine were measured using a commercial human CCL2 ELISA kit (R&D Systems, Bio-Techne, Minneapolis, USA) following the manufacturer’s instructions.

Techniques: